Hepatotoxicity induced by Droxicam: presentation of 4 cases
Morillas Ariño, J.; Sánchez de la Fuente, M.F.; García-Cano Lizcano, J.; Jiménez Sánchez, F.; Rosa Herranz, C.; Razquin Murillo, J.; Pérez Sola, A.; González Martín, J.A.
Revista Espanola de Enfermedades Digestivas Organo Oficial de la Sociedad Espanola de Patologia Digestiva 83(3): 197-201
1993
ISSN/ISBN: 1130-0108 PMID: 8489815 Document Number: 416732
Hepatotoxicity has been reported with most of the nonsteroidal antiinflammatory drugs (NSAID). We describe four patients who presented hepatic injury after of treatment with Droxicam, a new NSAID prodrug of piroxicam. Hepatitis was attributed to Droxicam because of the absence of other etiological factors, temporal relation with drug administration, clinical, laboratory and histological picture and evolution favorable after the drug suppression. The hepatic injury was manifested as cholestasis and withdrawal of the drug was followed by biochemical and clinical improvement until the complete normalization in three of the four patients. Postmarketing surveillance is necessary in new drugs with unknown hepatotoxicity.